Xenon (XENE) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Xenon Pharmaceuticals has unveiled promising long-term data from its X-TOLE study, showing that its drug azetukalner significantly reduces seizure frequency in patients with focal onset seizures. Impressively, one-third of those treated for over three years achieved complete seizure freedom, highlighting the drug’s potential to improve epilepsy treatment.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
